Lindt & Spruengli Shares Rise After Revenue Beats Views
By Nina Kienle
Shares of Chocoladefabriken Lindt & Spruengli rose after the company reported an increase in sales that exceeded analysts' expectations.
At 1040 GMT on Tuesday, shares were up 5.6% at EUR109.60.
The Swiss chocolatier said its preliminary results for 2023 show an increase in sales of 4.6% compared with the prior year to 5.20 billion Swiss francs ($6.08 billion) and sales grew 10% on an organic basis.
Analysts expected Lindt's revenue to be CHF5.16 billion, with organic growth of 9.2%, according to consensus estimates provided by FactSet.
All regions contributed to the growth, the company confirmed, with double-digit growth in North America and the rest of the world region.
The company confirmed its confidence in meeting its 2023 operating margin goal of around 15.5%, as well as increasing its operating margin for 2024 by 20-40 basis points with organic sales growth of 6% to 8%.
Lindt's strong 2023 figures and confident 2024 outlook should give the market confidence in the company's ambition to continue on a growth path despite headwinds, Stifel analyst Pascal Boll said in a research note.
Full-year results for 2023 are expected to be reported on March 5, the company said.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
January 16, 2024 06:04 ET (11:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?